Lakefront Biotherapeutics (LKFT) Shares Outstanding (Weighted Average) (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $344.1 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $344.1 million, up 11.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $344.1 million (up 11.3% YoY), and the FY2025 annual result was $342.2 million, up 8.93% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $344.1 million in Q1 2026 per LKFT's latest filing, from $342.2 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $344.1 million in Q1 2026 and troughed at $429.34 in Q1 2023.
• A 5-year average of $168.2 million and a median of $71.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) surged 194457823.85% in 2022, then slumped 100.0% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $67.0 million in 2022, then grew by 5.76% to $70.9 million in 2023, then jumped by 343.1% to $314.1 million in 2024, then rose by 8.93% to $342.2 million in 2025, then advanced by 0.58% to $344.1 million in 2026.
• Business Quant data shows LKFT's Shares Outstanding (Weighted Average) at $344.1 million in Q1 2026, $342.2 million in Q4 2025, and $343.6 million in Q3 2025.